Milestone for Bicycle Therapeutics from ophthalmic collaboration

29 May 2018

In a second deal expansion announced last week, Cambridge, UK-based Bicycle Therapeutics revealed the receipt of a milestone payment in connection with the initiation of a Phase I clinical study evaluating THR-149, under its ophthalmology alliance with Belgium’s ThromboGenics (Euronext Brussels: THR), a biopharmaceutical company focused on developing treatments for vitreo-retinal disorders.

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, last week also expanded its September 2013 collaboration with AstraZeneca (LSE: AZN), to include additional targets in respiratory and cardio-metabolic diseases.

THR-149 is a novel plasma kallikrein inhibitor identified and optimized by the Bicycle technology platform. The open-label, multicenter, dose escalation study will evaluate the safety of intravitreally administered THR-149 for the treatment of diabetic macular edema (DME). Initial study results are anticipated in mid-2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK